A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.
The infographic came to light Sunday. It includes data showing that total net sales at 340B price grew from $5.3 billion in 2010 to over $38 billion in 2020, and it projects that total net sales at 340B price will reach $197 billion in 2026. One in three brand drugs will be purchased at the 340B price by 2025, and 340B will be the largest federal drug program by 2026, it says.
A new two-pager about the 340B program by drug industry consultant Berkeley Research Group (BRG) indicates it was created for the 340B Industry Roundtable—an apparently new 340B drug industry stakeholder group.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.